Gemma Biotherapeutics
Latest round
- Seed
Last raised
- Dec 2024
Total raised
- $34M
Investors
- 4
About Gemma Biotherapeutics
, aka GemmaBio is dedicated to creating advanced gene therapies tailored to rare inherited conditions. The company was founded by its CEO, James M. Wilson. The company’s core offerings revolve around its proprietary adeno-associated virus (AAV) vectors, which have been engineered for gene transfer. These therapies are designed to treat a range of conditions, including cystic fibrosis, dyslipidemias, various neurologic disorders, and liver metabolic diseases, thereby targeting unmet medical needs within marginalized populations. The firm collaborates with Franklin Biolabs to expedite the research and delivery of these therapeutics, which are intended for global distribution, ensuring access for patients worldwide. GemmaBio's revenue model is primarily based on partnerships and collaborations within the biotechnology and pharmaceutical sectors. Revenue is generated through licensing agreements, research collaborations, and potentially revenue-sharing arrangements related to the commercialization of its gene therapies.
Who invested in Gemma Biotherapeutics
4 investors across 1 round
See all investors in Gemma Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Dec 23, 2024
Amount
$34M
Investors
Questions about Gemma Biotherapeutics
Who invested in Gemma Biotherapeutics?
Gemma Biotherapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gemma Biotherapeutics raised?
Gemma Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Gemma Biotherapeutics last raise money?
Gemma Biotherapeutics's most recent round on record is a Seed, in Dec 2024.
What does Gemma Biotherapeutics do?
, aka GemmaBio is dedicated to creating advanced gene therapies tailored to rare inherited conditions.
Where is Gemma Biotherapeutics headquartered?
Gemma Biotherapeutics is headquartered in Philadelphia, US.
Which VCs invest in companies like Gemma Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Gemma Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Gemma Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.